Hsiao FC, Lin CP, Tung YC, et al. - Risk of incident major adverse limb events appeared lower for patients with type 2 diabetes who initiated Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) relative to those who initiated sodium-glucose cotransporter-2 Inhibitors (SGLT2Is).

• From a multi-institutional database, researchers retrieved data of 3,087 patients for the GLP-1 RAs group and 19,101 patients for the SGLT2Is group.

• GLP-1 RAs appeared consistently beneficial in lowering major adverse limb events; the benefits did not alter in the presence or absence of cardiovascular disease or lower extremity arterial disease.

• Patients with type 2 diabetes who initiated GLP-1 receptor agonists had comparable incident major adverse cardiovascular events to those who initiated SGLT2 inhibitors.